Prospective Clinical Trial of Mycophenolate Mofetil (MMF) De-Escalation in Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Immunodeficiency (PID): MMF Is Dispensable in Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide(PTCy)-Based HCT

MLA

Dimana Dimitrova, et al. “Prospective Clinical Trial of Mycophenolate Mofetil (MMF) De-Escalation in Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Immunodeficiency (PID): MMF Is Dispensable in Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide(PTCy)-Based HCT.” Transplantation and Cellular Therapy, vol. 28, Mar. 2022, pp. S14–16. EBSCOhost, https://doi.org/10.1016/s2666-6367(22)00177-4.

APA

Dimana Dimitrova, Scott Napier, Jennifer Sponaugle, Anita Stokes, Mustafa Hyder, Gulbu Uzel, Luigi D. Notarangelo, Alexandra F. Freeman, Jenna R.E. Bergerson, Steven M. Holland, Mark Roschewski, Christopher Melani, Jeffrey I. Cohen, Andrea Lisco, Irini Sereti, Christa Zerbe, Amanda K. Ombrello, Deborah Stone, Jennifer Cuellar-Rodriguez, … Jennifer A. Kanakry. (2022). Prospective Clinical Trial of Mycophenolate Mofetil (MMF) De-Escalation in Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Immunodeficiency (PID): MMF Is Dispensable in Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide(PTCy)-Based HCT. Transplantation and Cellular Therapy, 28, S14–S16. https://doi.org/10.1016/s2666-6367(22)00177-4

Chicago

Dimana Dimitrova, Scott Napier, Jennifer Sponaugle, Anita Stokes, Mustafa Hyder, Gulbu Uzel, Luigi D. Notarangelo, et al. 2022. “Prospective Clinical Trial of Mycophenolate Mofetil (MMF) De-Escalation in Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Immunodeficiency (PID): MMF Is Dispensable in Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide(PTCy)-Based HCT.” Transplantation and Cellular Therapy 28 (March): S14–16. doi:10.1016/s2666-6367(22)00177-4.